Larotreni (Larotrectinib) 25mg/tablet*60tablets/bottle.

【Dosage form】

100mg/tablet*60tablets/bottle, 25mg/tablet*60tablets/bottle.

【Indications】

Larotrectinib is a broad-spectrum anticancer drug that is effective against many different types! It can effectively treat 17 types of tumors, including lung cancer, thyroid cancer, melanoma, gastrointestinal cancer, colon cancer, soft tissue sarcoma, salivary gland cancer, infantile fibrosarcoma, appendix cancer, breast cancer, bile duct cancer, osteosarcoma, pancreatic cancer, primary unknown cancer, and congenital mesodermal renal cancer. It is especially suitable for infantile fibrosarcoma and childhood osteosarcoma, with excellent results.

【Usage and Dosage】

Adults: Larotrectinib The dose of larotreni (Larotrectinib) for adults is 100 mg orally twice daily until disease progression or unacceptable toxicity.

Dosage for children based on age and weight: For pediatric patients with a body surface area less than 1.0 m2, the recommended dose of larotrectinib is 100 mg/m2, taken orally twice daily, with or without food.

If you miss a dose, you can take it again if it is more than 6 hours before the next dose. If you vomit after taking the medicine, you cannot take it again. You can take it again according to the original interval.

Adverse reaction dose adjustment: If a grade 3 or 4 adverse reaction occurs, reduce the dose until it improves or the adverse reaction reaches grade 1. If the adverse reaction improves within 4 weeks, resume at the next dose. If the adverse reaction does not subside within 4 weeks, permanently discontinue larotrectinib

【Adverse Reactions】

The most common side effects of larotrectinib include: fatigue, nausea, cough, constipation, diarrhea, dizziness, vomiting, and increased blood levels of the AST and ALT enzymes in the liver.

The majority of patients (93%) experienced grade 1 or 2 adverse events (AEs). There were no treatment-related grade 4 AEs, and the most common treatment-related grade 3 AEs included: ALT or AST increased (5%), anemia (2%), neutrophil count decreased (2%), nausea (2%), and dizziness (2%).

【Taboo】

This product is contraindicated in patients who are allergic to larotrectinib or any of its ingredients.

【Notes】

1. Nervous system problems; If you experience any adverse reactions, such as difficulty speaking, dizziness, coordination problems, tingling, numbness, or burning sensations in the hands and feet, please tell your healthcare provider. Your doctor may temporarily stop treatment, reduce your dose, or permanently stop larotrectinib.

2. Liver problems: Your healthcare provider will do blood tests to check liver function during treatment. If you develop liver problems, including: loss of appetite, nausea or vomiting, or pain in the upper right side of your stomach. Temporarily stop treatment, reduce your dose, or permanently stop

3. Pregnant or planning to become pregnant, larotrectinib may harm the unborn baby, you should not become pregnant during treatment. Women should use effective birth control (contraception) during treatment and for at least one week after the final dose. Discuss with your doctor the birth control methods that may be appropriate for you.

4. Breastfeeding. It is not known whether larotrectinib passes into your breast milk. Do not breastfeed during treatment and for one week after the last dose.

5. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how well larotrectinib works.

【Storage】

Store capsules at room temperature (20˚C to 25˚C)

Store the oral solution refrigerated (2°C to 8°C), do not freeze, the shelf life is 90 days, use within 90 days of first opening the bottle.

【Mechanism of action】

Currently, Larotreni ( larotrectinib) is a specific inhibitor for NTRK1, NTRK2 and NTRK3.

Safety and efficacy

According to data released by the FDA, 73% of patients responded for more than 6 months, 63% of patients responded for more than 9 months, and 39% of patients responded for more than 12 months.

In February 2018, the New England Journal of Medicine (NEJM), one of the world's four most authoritative medical journals, published three clinical studies on the safety and effectiveness of larotrectinib, showing that the overall efficacy of larotrectinib for patients aged 4 months to 76 years against 17 different types of cancer was 75%. This result was subsequently confirmed by the FDA.

At the European Society for Medical Oncology (ESMO 2018) meeting held in October 2018, clinical data on the anticancer drug larotrectinib in the treatment of adults and children with TRK fusion cancer covering 24 unique tumor types showed: overall response rate: 80%, partial response rate: 62%, complete response rate: 18%